Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019 | ||||||
By: Nasdaq / GlobeNewswire - 23 Apr 2019 | Back to overview list |
|||||
SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tuesday, May 7, 2019. During the call, Mark C. Capone, president and CEO, and Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial performance for the fiscal third-quarter and provide a business update. To listen to the earnings call, interested parties in the United States may dial 800-908-1487 or +1 303-223-0120 for international callers. All callers will be asked to reference reservation number 21920022. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call also will be available under the investor section of our website at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21920022. About Myriad Genetics Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
|
||||||
|
||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |